Recombinant Therapeutics Antibodies and Proteins Market size is projected to be growing at a valuation of USD 960.4 Billion by 2035; Increasing Demand for Personalized Medicine is Expected to Pitch the Market Growth

Download Sample

Published Date: April 2025

Recombinant therapeutic antibodies and proteins are genetically modified drugs that create highly specific, customized therapeutic molecules for illnesses. The recombinant therapeutics antibodies and proteins market is growing due to rising chronic disease prevalence, personalized medicine demand, biopharmaceutical research, biologics focus, and clinical trials. Improvements in genetic engineering, protein expression technologies, and new antibody technologies, such as bispecific antibodies and antibody-drug conjugates, further drive market growth.

Segmentation Analysis:

By Drug Class	Plasma Protein, Growth Factors, Fusion Protein, Monoclonal Antibodies, Hormones, Enzyme, Coagulation Factors, and Others
By Host Cell Type	Mammalian Cells, Bacterial Cells, Yeast Cells, and Others
By Application	Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others
By End User	Biotechnology and Pharmaceutical Companies, Research Organizations and Laboratories, Diagnostic Centers, and Others

Report Highlights:

Recombinant therapeutics antibodies and proteins market size is accounted at USD 227.4 Billion in 2025.
Target Market size is developing at a valuation of USD 960.4 Billion by 2034 and at a CAGR of 17.1%.
Based on drug class, the monoclonal antibodies is the drug class which is governing the recombinant therapeutics antibodies and proteins market share.
Dependent on host cell type, the mammalian cells is attributed to rule over the recombinant therapeutics antibodies and proteins market.
Based on application, the oncology segment is projected to dominate the recombinant therapeutics antibodies and proteins market.
On the basis of end user, the biotechnology and pharmaceutical companies is the end user which is leading the target market.
Under region, North America is the region which holds the superior recombinant therapeutics antibodies and proteins market share.
Europe is the region which is anticipated to grow with the fastest growth rate, during the forecast period, in the recombinant therapeutics antibodies and proteins market.

Market Dynamics:

Growing Factor	Challenge Factor	Market Trend
Rising Prevalence Of Chronic Diseases	Expression Complexity In Recombinant Therapeutics Antibodies And Proteins	Introducing New Therapeutic Targets

Key Highlights:

In October 2023, Proteintech, a global leader in antibodies, immunoassay kits, and recombinant proteins, announced the launch of Multi-rAb Recombinant Secondary Antibodies, the newest generation of secondary antibodies designed to deliver unparallel specificity and reproducibility in widely used immunoassays. Secondary antibodies are one of the most widely used reagents, making them indispensable tools for biomedical research.

Report Analysis:

Techniques of Production of Recombinant Proteins:

Genetic engineering, DNA cloning and vector design (e.g. plasmid vectors).
Transferring DNA sequences of interest into host cells (transformation into bacterial, yeast, mammalian or transfection into mammalian cells).
Protein expression and purification (e.g. with SDS-page or affinity chromatography).
Browse ∼30 market data tables and ∼55 figures through ∼170 slides and in-depth TOC on “Recombinant Therapeutics Antibodies and Proteins Market, By Drug Class (Plasma Protein, Growth Factors, Fusion Protein, Monoclonal Antibodies, Hormones, Enzyme, Coagulation Factors, and Others), Host Cell Type (Mammalian Cells, Bacterial Cells, Yeast Cells, and Others), Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), End User (Biotechnology and Pharmaceutical Companies, Research Organizations and Laboratories, Diagnostic Centers, and Others), and By Region - Trends, Analysis, and Forecast till 2035”

Segmentation:

By Drug Class:

Plasma Protein
Growth Factors
Fusion Protein
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

By Host Cell Type:

Mammalian Cells
Bacterial Cells
Yeast Cells
Others

By Application:

Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others

By End User:

Biotechnology and Pharmaceutical Companies
Research Organizations and Laboratories
Diagnostic Centers
Others

By Region:

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
- France
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- Indonesia
- Malaysia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa

For more insights into the Recombinant Therapeutics Antibodies and Proteins Market and its future trends, visit link below: https://www.prophecymarketinsights.com/market_insight/Global-Recombinant-Therapeutics-Antibodies-and-273

Competitive Landscape of Recombinant Therapeutics Antibodies and Proteins Market:

The key players operating in this market include Amgen Inc., Biogen, Sanofi, Abbott, Merck & Co., Inc., Eli Lilly and Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Pfizer Inc., Johnson & Johnson Services, Inc., Sino Biological, Inc., The Native Antigen Company, exonbio, and Bio-Techne.